Hyperbaric Chamber for Dementia: Can HBOT Improve Cognitive Function?

A meta-analysis of 25 randomized trials with nearly 2,000 patients found that adding HBOT to standard dementia treatment improved cognitive scores, daily living abilities, and neurological function. The mechanism appears to involve increased cerebral blood flow, reduced neuroinflammation, and amyloid plaque clearance. Evidence is strongest for vascular dementia and Alzheimer’s as an adjunct to medication. It is one of several other brain and neurological conditions HBOT may help currently being explored in clinical research.

How HBOT May Help Dementia

Dementia is driven by a combination of reduced blood flow to the brain, chronic inflammation, loss of neural connections, and (in Alzheimer’s disease) the accumulation of amyloid-beta plaques. HBOT addresses several of these pathways simultaneously, which is part of what makes it an interesting area of study. For a detailed breakdown, read the Alzheimer’s Association overview.

Increased Cerebral Blood Flow

One of the most consistent findings in dementia research is that patients have significantly reduced cerebral blood flow, sometimes called cerebral hypoperfusion. HBOT delivers oxygen at elevated pressure, saturating the blood plasma and reaching brain tissue that red blood cells may no longer supply effectively. SPECT imaging studies have confirmed that HBOT can increase perfusion in previously hypoxic brain regions.⁵ A 2019 RCT of 158 vascular dementia patients found HBOT at 2.0 ATA significantly improved MMSE scores while elevating serum Humanin – a neuroprotective peptide – with levels directly correlating to cognitive improvement (r=0.409, p<0.05).²

Neuroplasticity and Neurogenesis

HBOT has been shown to stimulate the release of brain-derived neurotrophic factor (BDNF) and promote the growth of new blood vessels (angiogenesis) in brain tissue. A 2020 study published in Aging demonstrated that HBOT could improve cerebral blood flow and microstructural brain changes in older adults, suggesting a neuroplasticity mechanism relevant for early-stage dementia patients.⁵ For a deeper dive, see our HBOT for brain health page.

Reduced Neuroinflammation

Chronic neuroinflammation is a hallmark of both Alzheimer’s and vascular dementia. Activated microglia release inflammatory cytokines that damage healthy neurons over time. A 2016 RCT of 82 early vascular dementia patients found HBOT significantly reduced CRP, IL-6, and TNF-gamma levels alongside improvements in cognitive, balance, and motor scores (p<0.05).⁴

Amyloid Clearance

Preclinical research suggests improved oxygenation and blood flow may support the brain’s glymphatic system, responsible for clearing amyloid-beta proteins. Shapira et al. (2021) found HBOT reduced amyloid plaque burden and improved spatial memory in an Alzheimer’s mouse model, while elderly patients with memory loss showed parallel cognitive improvements on imaging.⁶ Whether this translates to human patients remains an open question.

What Does the Research Say?

A meta-analysis of 25 randomized trials with nearly 2,000 patients found that adding HBOT to standard drug therapy improved Mini-Mental State Examination scores by 4 points and nearly quintupled the odds of treatment response with no increase in adverse events.”
You et al., 2019, Frontiers in Aging Neuroscience

The Key Meta-Analysis

The most comprehensive human evidence comes from You et al. 2019, a meta-analysis of 25 RCTs with 1,954 patients published in Frontiers in Aging Neuroscience.¹ The analysis tested HBOT combined with various standard medications (oxiracetam, butylphthalide, donepezil, nicergoline). Results:

• MMSE improvement: MD = 4.00 (95% CI 3.28-4.73, p<0.00001)
• ADL functional score: MD = -5.91 (95% CI -6.45 to -5.36, p<0.00001)
• Barthel Index ADL: MD = 13.86 (95% CI 5.63-22.10, p=0.001)
• Total treatment efficacy rate: OR = 4.84 (95% CI 3.19-7.33, p<0.00001)
• Adverse events: OR = 0.85 (p=0.79) – no significant increase

The Cochrane Review and Its Context

The 2012 Cochrane Review, which included only one small study (64 patients), concluded there was “insufficient evidence” to support HBOT for vascular dementia.³ That review has not been updated since. The You 2019 meta-analysis, which included 25 times as many trials and nearly 30 times as many patients, provides a more complete picture. The difference illustrates how quickly this field has evolved.

Honest Assessment of the Evidence

It is important to state clearly: no large-scale, multi-center Western randomized controlled trial has confirmed HBOT as an effective standalone treatment for any form of dementia. Most studies in the You 2019 meta-analysis were conducted in China. Many have methodological limitations regarding blinding. The field needs larger trials with sham-controlled designs, longer follow-up periods, and standardized outcome measures. Families considering HBOT for a loved one should understand this is an emerging area, not an established standard of care. For a deeper look at Alzheimer’s-specific research, see our dedicated page on hyperbaric chambers for Alzheimer’s patients.

Types of Dementia That May Respond to HBOT

Vascular Dementia

Vascular dementia is caused by reduced blood flow to the brain, often from small vessel disease or stroke. Because HBOT directly addresses cerebral hypoperfusion, the theoretical rationale for this form of dementia is the strongest. The You 2019 meta-analysis specifically covered vascular dementia patients. If you are exploring HBOT for brain-related conditions, our page on hyperbaric chambers for brain injury covers related mechanisms. This is also explored in our stroke recovery page.

Alzheimer’s Disease

Alzheimer’s has a more complex pathology involving amyloid plaques, tau tangles, and neuroinflammation. The evidence for HBOT in Alzheimer’s is more preliminary, but the Shapira et al. (2021) data and several preclinical models provide early support. The overlap between vascular dysfunction and Alzheimer’s means many Alzheimer’s patients may benefit from the same blood flow improvements.

Lewy Body Dementia

There is very limited data on HBOT for Lewy body dementia specifically. No clinical trials have studied this population. Any consideration of HBOT for Lewy body dementia should be discussed with a neurologist familiar with the condition.

Dementia Type	Evidence Level	Strongest Rationale	Key Studies
Vascular dementia	Moderate (as adjunct)	Direct CBF improvement	You 2019 meta-analysis (25 RCTs)
Alzheimer’s disease	Weak-Moderate	Amyloid clearance, inflammation	Lin 2024 meta-analysis (11 RCTs)
Mixed dementia	Weak	Combined vascular + AD mechanisms	Extrapolated from above
Lewy body dementia	Insufficient evidence	Theoretical only	No dedicated trials

Treatment Protocols for Dementia

Most clinical studies on HBOT for cognitive decline and dementia have used similar protocols:

• Number of sessions: 40 to 60 sessions, with many studies using 60 as the standard course.
• Pressure: 1.5 to 2.0 ATA. The You 2019 meta-analysis studies typically used 2.0 ATA with standard medications.
• Session duration: 60 minutes of oxygen breathing at pressure, not counting compression and decompression time.
• Frequency: 5 sessions per week (Monday through Friday), making a 60-session course approximately 12 weeks long.
• Maintenance: Some clinicians recommend periodic sessions after the initial course, though optimal maintenance protocols have not been established. Our guide on how long HBOT effects last covers duration of benefits.

For a broader overview of what sessions look like, visit our HBOT sessions guide.

What Does the HBOT Protocol Look Like?

Realistic Timeline

Cognitive improvements from HBOT, when they occur, typically do not appear after just a few sessions. Most studies report measurable changes after 40 or more sessions. Families should plan for a commitment of at least three months before evaluating whether HBOT is helping.

Who Might Benefit Most

Based on the available evidence, patients most likely to see improvement include:

• Those with vascular dementia or mixed dementia (vascular plus Alzheimer’s components).
• Patients in early to moderate stages of cognitive decline rather than advanced dementia.
• Individuals who can tolerate a consistent five-day-per-week schedule.
• Patients whose families understand results are not guaranteed and approach HBOT as a complementary option alongside standard medications.

Who Should Not Try HBOT

HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting.

Absolute Contraindications

• Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
• Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments

Relative Contraindications

• Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
• Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
• Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
• High fever – increases the risk of oxygen toxicity
• History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
• Claustrophobia – may require sedation or use of a multiplace chamber instead
• Pregnancy – insufficient safety data exists for routine use during pregnancy

Talk to Your Doctor First

Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin, have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.

Sources

1. You Q, Li L, Xiong SQ, et al. “Meta-Analysis on the Efficacy and Safety of Hyperbaric Oxygen as Adjunctive Therapy for Vascular Dementia.” Frontiers in Aging Neuroscience. 2019;11:86. DOI: 10.3389/fnagi.2019.00086
2. Xu Y, Wang Q, Qu Z, et al. “Protective Effect of Hyperbaric Oxygen Therapy on Cognitive Function in Patients with Vascular Dementia.” Cell Transplantation. 2019;28(8):1071-1075. DOI: 10.1177/0963689719853540
3. Xiao Y, Wang J, Jiang S, Luo H. “Hyperbaric oxygen therapy for vascular dementia.” Cochrane Database of Systematic Reviews. 2012;(7):CD009425. DOI: 10.1002/14651858.CD009425.pub2
4. He X, Deng J. “Effect of early hyperbaric oxygen therapy on advanced brain function and inflammatory factors in patients with vascular dementia.” 2016.
5. Hadanny A, Daniel-Kotovsky M, Suzin G, et al. “Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.” Aging. 2020;12(13):13740-13761. DOI: 10.18632/aging.103571
6. Shapira R, Gdalyahu A, Gottfried I, et al. “Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer’s disease mouse model and in elderly patients.” Aging. 2021;13(16):20935-20969. DOI: 10.18632/aging.203485
7. Alhewiti A. “Effectiveness of HBOT for Treating Neurodegenerative and Non-neurodegenerative Dementia.” South East European Journal of Public Health. 2025. DOI: 10.70135/seejph.vi.4828